Form 4: Centessa Pharmaceuticals' General Counsel, Iqbal Hussain, Reports Changes in Beneficial Ownership

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the disposal of 7,520 ordinary shares to cover tax withholding obligations related to vesting restricted share units on March 31, 2024.

Summary

• On March 31, 2024, Iqbal Hussain, the General Counsel of Centessa Pharmaceuticals, reported a change in beneficial ownership of the company's ordinary shares.
• The transaction involved the disposal of 7,520 ordinary shares at a price of $11.3 per share.
• These shares were withheld by Centessa Pharmaceuticals to cover tax withholding obligations associated with the vesting of restricted share units.
• Following the transaction, Hussain directly owns 212,530 ordinary shares and indirectly owns 5,500 ordinary shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to executive stock transactions and does not convey any particularly positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and does not necessarily indicate a significant trend or event within the pharmaceutical industry.

Comparison to Industry Standards

• Similar transactions are common among executives in publicly traded companies, particularly in the pharmaceutical sector, as part of their compensation packages.
• Companies like Pfizer, Johnson & Johnson, and Merck also regularly report similar transactions by their executives.
• The number of shares disposed of is relatively small compared to the total shares owned by Hussain, suggesting this is a standard tax-related transaction rather than a strategic move.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors, as it is a routine executive stock transaction.

Key Dates